Clinical Trials

51 enrolled

Leukemia, Myeloid, Acute

NCT04988555 2026-03-24

A Phase 1/2 Study of Enzomenib (DSP-5336) in Patients With Acute Leukemia (Horizen-1)

LymphoidMyeloidOther hematologic neoplasmPlasma cell

606 enrolled

Multiple Myeloma, Myelodysplastic Syndromes, Recurrence, Leukemia, Myeloid, Acute, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT06220162 2026-03-19

VAC Regimen for AML Patients Who Failed to Response to VA Regimen

32 enrolled

Leukemia, Myeloid, Acute

NCT06379360 2026-03-19

Maintenance Therapy of Hypomethylating Agent (HMA) in Favorable Risk Acute Myeloid Leukemia (AML) Patients

77 enrolled

Leukemia, Myeloid, Acute

NCT04588922 2026-03-16

Study of SLS009 (Formerly GFH009) a Potent Highly Selective CDK9 Inhibitor in Patients With Hematologic Malignancies and High-Risk Newly Diagnosed AML

LymphoidOther hematologic neoplasm

160 enrolled

Lymphoma, Recurrence, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Myeloid, Acute, Hematologic Neoplasms

NCT05735184 2026-03-13

A Study to Investigate the Safety and Tolerability of Ziftomenib in Combination With Venetoclax/Azacitidine, Venetoclax, 7+3, or 7+3+Quizartinib in Patients With AML

Other hematologic neoplasmSarcoma

420 enrolled

Leukemia, Leukemia, Myeloid, Acute, Hematologic Neoplasms, Sarcoma, Myeloid

NCT06557421 2026-03-13

STOP VEN

50 enrolled

Leukemia, Myeloid, Acute

NCT03471260 2026-03-11

Ivosidenib and Venetoclax With or Without Azacitidine in Treating Patients With IDH1 Mutated Hematologic Malignancies

96 enrolled

Myelodysplastic Syndromes, Myeloproliferative Disorders, Leukemia, Myeloid, Acute

NCT05834244 2026-03-11

A Phase Ib Trial of Azacitidine, Venetoclax and Allogeneic NK Cells for Acute Myeloid Leukemia (ADVENT-AML)

32 enrolled

Leukemia, Myeloid, Acute

NCT06456463 2026-03-09

TRILLIUM

83 enrolled

Leukemia, Myeloid, Acute

NCT06548230 2026-03-09

A Phase 1B/2A Trial of NADUNOLIMAB in Combination With Azacitidine (With/Without Venetoclax) in Patients With Myelodysplastic Syndrome (MDS) and Acute Myelogenous Leukemia (AML)

40 enrolled

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute

NCT07392242 2026-03-06

A Study of the Combination of Ivosidenib, Azacitidine, and Venetoclax Followed by Ivosidenib Alone in People With Acute Myeloid Leukemia

45 enrolled

Leukemia, Myeloid, Acute

NCT03683433 2026-03-05

Enasidenib and Azacitidine in Treating Patients With Recurrent or Refractory Acute Myeloid Leukemia and IDH2 Gene Mutation

50 enrolled

Myelodysplastic Syndromes, Leukemia, Biphenotypic, Acute, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic

NCT06498973 2026-03-05

Tagraxofusp and Azacitidine for Maintenance Treatment in Patients With CD123 Positive AML and MDS Following Donor Hematopoietic Cell Transplant

43 enrolled

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute

NCT07304011 2026-03-05

Olutasidenib With Azacitidine Followed by Olutasidenib Maintenance for the Treatment of IDH1-mutated Acute Myeloid Leukemia in Patients With Prior Treatment With Venetoclax Plus a Hypomethylating Agent

28 enrolled

Leukemia, Myeloid, Acute

NCT06177067 2026-03-04

Study of Revumenib, Azacitidine, and Venetoclax in Pediatric and Young Adult Patients With Refractory or Relapsed Acute Myeloid Leukemia

24 enrolled

Leukemia, Biphenotypic, Acute, Leukemia, Myeloid, Acute

NCT06483906 2026-03-03

Venetoclax and Azacitidine Combined With Homoharringtonine, Followed by Allo-HSCT for Intermediate and High-risk AML.

56 enrolled

Leukemia, Myeloid, Acute

NCT06370000 2026-03-02

REMAIN1

Phase 4 Recruiting

12 enrolled

Leukemia, Myeloid, Acute

NCT07132684 2026-03-02

Comparison of VA and D/IA Induction Regimens in Elderly Fit Acute Myeloid Leukemia Patients

Phase 3 Recruiting

240 enrolled

Leukemia, Myeloid, Acute

NCT06511882 2026-02-27

Discontinuation of Hypomethylating Agent and Venetoclax in Patients With AML MRD

37 enrolled

Leukemia, Myeloid, Acute

NCT06445907 2026-02-24

Phase I Study of Q702 With Azacitidine and Venetoclax for Relapsed or Refractory Acute Myeloid Leukemia

32 enrolled

Leukemia, Myeloid, Acute

NCT06773208 2026-02-24

A Study of Azacitidine and Venetoclax in People With Acute Myeloid Leukemia (AML)

30 enrolled

Leukemia, Myeloid, Acute

NCT06616636 2026-02-18

A Phase Ib Study of Rezatapopt in Combination With Azacitidine in Patients With TP53Y220C Mutant Myeloid Malignancies (Acute Myeloid Leukemia or Myelodysplastic Syndrome)

24 enrolled

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute

NCT03383575 2026-02-17

Azacitidine and Enasidenib in Treating Patients With IDH2-Mutant Myelodysplastic Syndrome

Classical hematologyOther hematologic neoplasm

63 enrolled

Anemia, Refractory, with Excess of Blasts, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic

NCT07148180 2026-02-05

A Multi-Site Break Through Cancer Trial: Targeting Measurable Residual Disease in Patients With Acute Myeloid Leukemia: A Phase 1/2 Study of Tagraxofusp, Azacitidine, and Venetoclax

31 enrolled

Leukemia, Leukemia, Myeloid, Acute, Neoplasm, Residual, Hematologic Neoplasms

NCT06372717 2026-02-04

A Study to Investigate APL-4098 Alone and in Combination in Adults With AML or MDS

Classical hematologyOther hematologic neoplasm

100 enrolled

GATA2 Deficiency, Anemia, Refractory, with Excess of Blasts, Leukemia, Myeloid, Acute

NCT05183035 2026-01-13

Venetoclax in Children With Relapsed Acute Myeloid Leukemia (AML)

Phase 3 Recruiting

98 enrolled

Leukemia, Myeloid, Acute

NCT07044687 2026-01-12

Study to Assess Adverse Events and Change in Disease Activity of Oral Venetoclax in Combination With Subcutaneous (SC) or Intravenous (IV) Azacitidine in Newly Diagnosed Adult Participants With Acute Myeloid Leukemia (AML) Who Are Ineligible for Standard Induction Therapy in India

Phase 4 Recruiting

100 enrolled

Leukemia, Myeloid, Acute

NCT07320235 2026-01-06

IMAGINE

36 enrolled

Leukemia, Myeloid, Acute

NCT06232655 2025-12-19

Cladribine Venetoclax in Monocytic AML

20 enrolled